Facebook Instagram Linkedin Youtube
Home Search

saniona - search results

If you're not happy with the results, please do another search
Saniona’s CEO: “The deal promotes our position in the industry”

Saniona’s CEO: “The deal with Acadia is significant”

Saniona's tesofensine yet to be approved

Saniona provided a tesofensine update

Saniona achieves milestone with Boehringer Ingelheim

Saniona achieves milestone with Boehringer Ingelheim

Saniona has started dosing in the SAN711 trial

Saniona has started dosing in the SAN711 trial

Saniona’s CEO: “SAN2355 is a highly promising candidate for commercialization”

Saniona’s CEO: “SAN2355 is a highly promising candidate for commercialization”

Saniona comments on the approval to initiate epilepsy study

Saniona comments on the approval to initiate epilepsy study

Saniona siktar på nya kliniska data och ett första marknadsgodkännande

Saniona aiming for new clinical data and first market approval

Saniona’s CEO: “The deal promotes our position in the industry”

Saniona’s CEO: “We have meetings with potential partners every week”

Saniona’s CEO: “The deal promotes our position in the industry”

Saniona’s CEO: “Our development pipeline is stronger than ever”

Saniona’s CEO: “The deal promotes our position in the industry”

Saniona raises capital to advance epilepsy programme

Medivir's CEO comments on the latest developments

Saniona carves path to disrupt the epilepsy market

Saniona

BioStock Investor Pitch: Saniona

Saniona’s CEO: “financing will bring SAN711 towards proof of concept”

Saniona’s CEO: “financing will bring SAN711 towards proof of concept”

After encouraging results showing rapid reversal of stress-induced depression, Saniona selects SAN2465 as a clinical candidate for major depressive disorder. The announcement comes less than a week after Saniona chose SAN2355 as the first clinical candidate from its Kv7 epilepsy program. BioStock reached out to Saniona’s CEO Thomas Feldthus for a comment.

Saniona selects clinical candidate for major depressive disorder

Saniona on the new epilepsy candidate SAN2355

Saniona on the new epilepsy candidate SAN2355

Saniona’s CEO shares 2024 business development roadmap

Saniona’s CEO shares 2024 business development roadmap

Aptahem

Saniona made further progress during Q3

Saniona comments on the approval to initiate epilepsy study

Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments”

Saniona_AstronauTx_capital_raise

Saniona’s take on AstronauTx’s capital raise

BioInvent soon has five drug candidates in six clinical studies

Saniona´s CEO comments on the collaboration with AstronauTx

Top five life science stocks during the first half-year

The five best life science stocks of the first half-year

Saniona sees potential for value-creating milestones

Comback seen for biotech stocks

Analysis sees brighter times ahead for biotech

Saniona's tesofensine yet to be approved

Saniona´s obesity drug one step closer to approval

Saniona Cephagenix Migraine Collaboration

Saniona and Cephagenix comment on their joint migraine programme

The value of patent protection in life science

The value of patent protection in life science

PHI grows its network of collaborations

Saniona ready for phase I with SAN903

Iconovo

Saniona receives heightened interest in Q2

Saniona ready to advance its Kv7 programme

Saniona reports positive results

Positive phase I results for Saniona

Top five life science stocks during the first half-year

Biotech companies traded below cash

Saniona on the paused Tesomet programmes and restructuring

Stockholm's five top and bottom life science shares in Q1 2022

Stockholm’s five top and bottom life science shares in Q1

Saniona Q4

Saniona’s Q4 Signals Value Ahead

Saniona

Saniona reaches milestone in SAN711 study

Saniona starts 2022 with three clinical trials

Saniona begins 2022 with three clinical trials ongoing

Immunicum finalises phase I ILIAD trial

Saniona initiates clinical trial in rare disease

BioStock studio: Saniona celebrates a decade of progress

Saniona’s founder on 10 years of history and the future

BioStock Life Science Summit 20 – 21 Oktober 2021

Join us for the BioStock Life Science Summit on October 20...

FDA

Saniona one step closer to clinical studies in HO and PWS

Saniona strengthens its board of directors

Saniona’s new CBO on strategy and business development

Saniona’s clinical and regulatory progress during H1

FDA

Saniona’s CMO on the FDA Orphan Drug Designation for Tesomet in...

BrainCool

Saniona trailblazing towards market approval

Saniona’s CEO has high-flying plans

Strong first half of 2020 for Scandion Oncology

Saniona’s CEO on the USD 65 million capital raise

Saniona strengthens US executive team with three industry veterans

Sainona’s CEO: Saniona gains momentum advancing Tesomet for two rare diseases

Scandion Oncology strengthens executive leadership

BioStock studio: Saniona’s chairman aims to recruit America’s best talents

Strong signals from Saniona in rare disease

Saniona comments on the possible listing in the USA

Saniona’s CEO on the plans for 2021

BioStock studio: Saniona´s CFO on his visions for the company

Saniona’s CMO on the new clinical trial with SAN711

Saniona’s CEO on progress in 2020 and the way forward

Saniona’s CEO on year-end results and the company’s long-term goals

12Page 1 of 2
© BioStock 2024